scFv-Transferrin Fusion Protein for Barrier-Crossing Antibody Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Many antibodies face challenges in crossing biological barriers such as the blood-brain barrier and blood-eye barrier, and entering cancerous cells due to their size and lack of specific targeting mechanisms, limiting their efficacy and application in certain diseases.
Innovation Solution
A single-chain variable fragment (scFv) antibody is designed to conjugate with the N-methyl lobe of transferrin protein, utilizing transferrin receptor-mediated endocytosis for enhanced cellular uptake and incorporating cleavable linkers to ensure targeted delivery and release within specific cellular environments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a whole antibody is used, then immune effector functions and half-life are enhanced, but cellular penetration and crossing biological barriers is hindered
Solution Approach 1:
The antibody is segmented into functional components: the scFv fragment retains antigen-binding capability while the Fc region is modified or removed. This segmentation allows the antibody to cross biological barriers more effectively while maintaining necessary binding functions through the scFv portion.
Solution Approach 2:
Transferrin is used as an intermediary protein to facilitate cellular uptake. The scFv-transferrin fusion protein utilizes the transferrin receptor-mediated endocytosis pathway, where transferrin acts as a mediator to enable efficient delivery into cells, particularly cancer cells with high transferrin receptor expression.
2Length of moving object
If a scFv is used, then cellular penetration is improved, but immune effector functions are lost
Solution Approach 1:
Transferrin serves as a mediator that compensates for the loss of Fc region-mediated immune effector functions. The fusion protein utilizes transferrin receptor-mediated endocytosis to achieve cellular internalization, providing an alternative mechanism for cellular penetration and potential therapeutic effect.
Solution Approach 2:
The scFv-transferrin fusion protein combines multiple functions: antigen binding through scFv, cellular uptake through transferrin receptor interaction, and potential intracellular delivery. This multi-functionality allows the protein to achieve both penetration and therapeutic efficacy.
3Manufacturing precision
If antibody conjugation is used, then targeted delivery is improved, but manufacturing complexity increases
Solution Approach 1:
The scFv and transferrin are merged into a single fusion protein through genetic engineering, creating a stable conjugate that maintains targeted delivery capability. This merging approach simplifies the conjugation process compared to chemical conjugation methods while preserving the targeting function through the scFv-transferrin interaction.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The scFv-transferrin fusion protein enhances cellular penetration, improves therapeutic efficacy by reducing off-target effects, and allows for controlled release of therapeutic agents in target cells, thereby increasing treatment effectiveness.
Implementation Method 1
utilizing transferrin receptor-mediated endocytosis for enhanced cellular uptake
Implementation Method 2
incorporating cleavable linkers to ensure targeted delivery and release within specific cellular environments
Implementation Method 3
incorporating cleavable linkers to ensure targeted delivery and release within specific cellular environments
Data Source
AI summary
The efficacy and indication of tildrakizumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.